| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1040910102 |
| P356 | DOI | 10.2165/00003088-200645010-00003 |
| P698 | PubMed publication ID | 16430310 |
| P50 | author | Jan H M Schellens | Q89824209 |
| Jos Beijnen | Q23771643 | ||
| Jan H Beumer | Q49531403 | ||
| P2860 | cites work | Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lometrexol) administered with an oral folic acid supplement | Q77555405 |
| Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose | Q77959279 | ||
| The fate of 6-mercaptopurine in man | Q78573330 | ||
| Preliminary studies on the distribution and fate of TEM, TEPA, and myleran in the human | Q78844559 | ||
| The absorption, distribution, excretion, and biotransformation of the carcinostatic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in animals | Q93803730 | ||
| Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans | Q28324506 | ||
| A phase I clinical, plasma, and cellular pharmacology study of gemcitabine | Q28334915 | ||
| Clinical and preclinical pharmacokinetics of raltitrexed. | Q30653901 | ||
| Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites | Q32117273 | ||
| Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function | Q33179062 | ||
| Metabolism, excretion and pharmacokinetics of a single dose of [14C]-raltitrexed in cancer patients | Q33502692 | ||
| Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom | Q33546258 | ||
| Monitoring pharmacokinetics of anticancer drugs: non-invasive investigation using magnetic resonance spectroscopy | Q33852965 | ||
| Clinical pharmacokinetics of oxaliplatin: a critical review | Q33898003 | ||
| Recent advances in the applications of radioisotopes in drug metabolism, toxicology and pharmacokinetics | Q33927729 | ||
| Accelerator mass spectrometry in pharmaceutical research and development--a new ultrasensitive analytical method for isotope measurement | Q34314738 | ||
| Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review | Q34407987 | ||
| Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. | Q34745419 | ||
| Big physics, small doses: the use of AMS and PET in human microdosing of development drugs | Q35075780 | ||
| The complexities of hepatic drug transport: current knowledge and emerging concepts. | Q35793721 | ||
| Kinetics of intravenous melphalan | Q38537678 | ||
| The bioavailability in man of ICRF-159 a new oral antineoplastic agent | Q39077425 | ||
| Fate of streptozotocin (NSC-85998)in patients with advanced cancer | Q39753749 | ||
| Current perspectives of 14 C-isotope measurement in biomedical accelerator mass spectrometry | Q40548802 | ||
| Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative | Q41123160 | ||
| Preclinical, pharmacologic, and phase I studies of gemcitabine | Q41508255 | ||
| Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods | Q42036624 | ||
| Species variations in the threshold molecular-weight factor for the biliary excretion of organic anions | Q42118948 | ||
| Metabolism profiles and excretion of14C-aminoglutethimide in several animal species and man | Q42213570 | ||
| Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile | Q42224174 | ||
| Disposition and metabolism of thiopurines. II. Arabinosyl-6-mercaptopurine and ribosyl-6-mercaptopurine | Q42230784 | ||
| Pharmacokinetics and metabolism of vinblastine in humans | Q42596745 | ||
| Pharmacokinetics and metabolism of formestane in breast cancer patients | Q43612166 | ||
| Excretion and metabolism of desogestrel in healthy postmenopausal women. | Q43819134 | ||
| Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients | Q43824959 | ||
| A comparison of quantitative NMR and radiolabelling studies of the metabolism and excretion of Statil (3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-ylacetic acid) in the rat. | Q43892978 | ||
| Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a far | Q44028575 | ||
| Urinary and fecal excretion of topotecan in patients with malignant solid tumours | Q44058880 | ||
| Pharmacokinetics and metabolism of the anti-oestrogen droloxifene in female human subjects | Q44150762 | ||
| An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients | Q44190160 | ||
| Pharmacokinetics and metabolism of chlorambucil in patients with malignant disease | Q44577584 | ||
| The disposition of carboplatin in ovarian cancer patients | Q44959628 | ||
| Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment | Q45036142 | ||
| Protocol development for biological tracer studies | Q46331540 | ||
| PTG, a new antineoplastic epipodophyllotoxin | Q48447875 | ||
| Pharmacokinetics of actinomycin 0 in patients with malignant melanoma | Q48457648 | ||
| Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA) in cancer patients | Q51609144 | ||
| Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant diseas | Q51609240 | ||
| Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14 | Q52163906 | ||
| Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo. | Q52163988 | ||
| Studies on OPSPA. IV. Metabolism of OPSPA in the rat and human. | Q52164022 | ||
| Studies on OPSPA. III. Distribution and excretion of radioactivity following administration of OPSPA-C14 and OPSPA-P32 to humans. | Q52164028 | ||
| Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates alpha-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. | Q53470768 | ||
| Distribution of tritiated daunomycin in man by a simplified method. | Q53942499 | ||
| The absorption metabolism, and excretion of Estracyt (NSC 89199) in patients with prostatic cancer. | Q54377666 | ||
| Pharmacokinetics and metabolism of beta-2'-deoxythioguanosine and 6-thioguanine in man. | Q54523619 | ||
| Distribution and excretion of adriamycin in man. | Q54763450 | ||
| Pharmacokinetic equivalence of stable-isotope-labeled and unlabeled drugs. Phenobarbital in man | Q58011211 | ||
| The pharmacokinetics of 4-acetyl tritium vinblastine in two patients | Q66912755 | ||
| Pharmacokinetics and metabolism of chlorambucil in man: a preliminary report | Q66957121 | ||
| EPEG, a new antineoplastic epipodophyllotoxin | Q67244197 | ||
| Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease | Q67326600 | ||
| The pharmacokinetics of [3H]-vincristine in man | Q67674473 | ||
| Oral administration of [3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods | Q67867951 | ||
| The inspection of drug metabolism and pharmacokinetic studies | Q67878183 | ||
| Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partitioning technique | Q67993409 | ||
| The metabolic fate of tritiated methotrexate. II. Absorption and excretion in man | Q68552830 | ||
| Biliary excretion and pharmacokinetics of 4'epidoxorubicin (epirubicin) in advanced cancer patients | Q68737201 | ||
| Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans | Q69038585 | ||
| Clinical pharmacology of isophosphamide | Q69352991 | ||
| The metabolism of tamoxifen (I.C.I. 46,474). II. In female patients | Q69665945 | ||
| Dechloroethylation of ifosfamide and neurotoxicity | Q69889353 | ||
| Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma | Q69936079 | ||
| Complete urinary excretion profile of 5-fluorouracil during a six-day chemotherapeutic schedule, as resolved by 19F nuclear magnetic resonance | Q69945661 | ||
| The physiological disposition of the carcinostatic 1,3-bis(2-chloroethyU-l-nitrosourea (BCNU) in man and animals | Q69973848 | ||
| Human urinary excretion of doxifluridine and metabolites during a 5-day chemotherapeutic schedule using fluorine-19 nuclear magnetic resonance spectrometry | Q70039903 | ||
| Disposition of mitoxantrone in cancer patients | Q70070391 | ||
| Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function | Q70331159 | ||
| Disposition of orally administered 14C-prednimustine in cancer patients | Q71097601 | ||
| Disposition of mitoxantrone in patients | Q71165481 | ||
| Metabolism of a new synthetic progestagen, Org 2969, in female volunteers. The distribution and excretion of radioactivity after an oral dose of the labelled drug | Q71201141 | ||
| Human pharmacokinetics of a new acridine derivative, 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) | Q71244465 | ||
| Preliminary Studies on the Distribution and Excretion of Tritiated Daunomycin in Men | Q71323877 | ||
| Taxol metabolism and disposition in cancer patients | Q71845211 | ||
| Distribution and excretion studies of procarbazine in animals and man | Q72007872 | ||
| Metabolic fate of tritiated busulfan in man | Q72336119 | ||
| Pharmacokinetics of bleomycin after im administration in man | Q72636035 | ||
| A regulatory and industrial perspective of the use of carbon-14 and tritium isotopes in human ADME studies | Q72746311 | ||
| Mass balance and metabolism of [(3)H]Formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation | Q73019165 | ||
| A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug | Q73166083 | ||
| Analysis of DNA adducts by accelerator mass spectrometry in human breast tissue after administration of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and benzo[a]pyrene | Q73290138 | ||
| Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours | Q73322472 | ||
| A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts | Q73327887 | ||
| Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration | Q73356500 | ||
| Elimination pathways of [14C]losoxantrone in four cancer patients | Q73400204 | ||
| Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients | Q73566821 | ||
| Excretion balance and metabolism of the progestagen Org 30659 in healthy postmenopausal women | Q73815875 | ||
| Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer | Q74484378 | ||
| The role of DNA adducts in chemical carcinogenesis | Q74801831 | ||
| The metabolic fate of C14-progesterone in human subjects | Q74820493 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 33-58 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Clinical Pharmacokinetics | Q5133788 |
| P1476 | title | Mass balance studies, with a focus on anticancer drugs | |
| P478 | volume | 45 |
| Q54523392 | A perspective on tritium versus carbon-14: ensuring optimal label selection in pharmaceutical research and development. |
| Q48090720 | A phase I study to investigate the metabolism, excretion, and pharmacokinetics of [14C]fruquintinib, a novel oral selective VEGFR inhibitor, in healthy Chinese male volunteers |
| Q53391849 | Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers. |
| Q33819361 | Accelerator mass spectrometry-enabled studies: current status and future prospects |
| Q96308313 | An integrated assessment of the ADME properties of the CDK4/6 Inhibitor ribociclib utilizing preclinical in vitro, in vivo, and human ADME data |
| Q37963912 | Bioanalytical aspects of clinical mass balance studies in oncology |
| Q48225243 | Deuterium- and Tritium-Labelled Compounds: Applications in the Life Sciences. |
| Q53744026 | Disposition and metabolism of [14C]-galunisertib, a TGF-βRI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics. |
| Q41880361 | Human absorption, distribution, metabolism and excretion properties of drug molecules: a plethora of approaches |
| Q36619557 | Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry |
| Q35884220 | Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. |
| Q90665165 | Mass balance and metabolite profiling of 14C-guadecitabine in patients with advanced cancer |
| Q51431945 | Metabolism and disposition of a novel antineoplastic JS-38 (Benzamide, N-[4-(2,4-dimethoxyphenyl)-4,5-dihydro-5-oxo-1,2-dithiolo[4,3-b]pyrrol-6-yl]-3,5-bis (trifluoromethyl)-(9Cl)) in rats. |
| Q54337355 | Metabolism, excretion and pharmacokinetics of [14C]crizotinib following oral administration to healthy subjects. |
| Q34257497 | Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. |
| Q27011795 | Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites |
| Q37222797 | Pharmacokinetics and excretion of (14)C-omacetaxine in patients with advanced solid tumors |
| Q34322781 | Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy |
| Q46610678 | Pharmacokinetics, metabolism, and excretion of (14)C-labeled belinostat in patients with recurrent or progressive malignancies |
| Q45383453 | Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients |
| Q38836158 | Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review |
| Q35235758 | Technologies and strategies to characterize and quantitate metabolites in drug discovery and development |
| Q90085722 | The Importance of the Human Mass Balance Study in Regulatory Submissions |
| Q37065418 | The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studies |
| Q48828667 | The pharmacokinetics of JS-38, a novel antineoplastic drug, in rats |
| Q51027263 | Utilizing 19F NMR to investigate drug disposition early in drug discovery. |
| Q33278984 | What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs |
Search more.